EICHOR
● Active Not Recruiting
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Transitional Cell Carcinoma · Fallopian Tube Undifferentiated Carcinoma · Sponsor: National Cancer Institute (NCI)
About this study
This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (356)
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | — |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| Arizona Oncology Associates-West Orange Grove | Tucson, Arizona, United States | — |
| Arizona Oncology Associates-Wilmot | Tucson, Arizona, United States | — |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | — |
| PCR Oncology | Arroyo Grande, California, United States | — |
| Mercy San Juan Medical Center | Carmichael, California, United States | — |
| Marin Cancer Care Inc | Greenbrae, California, United States | — |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | — |
+ 344 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.